What Actually Scales in AI-Driven Healthcare: From Hype to Real-World Impact
Panel Discussion with Four Panelists
Join us for a timely conversation featuring four leaders at the forefront of healthcare, technology, venture capital, and biotechnology. Jeff Tangney, CEO of Doximity, brings the perspective of a scaled digital health platform used by clinicians nationwide. Reema Khan, Founder and CEO of Green Sands Equity, offers a global investor’s perspective on frontier technologies and capital allocation. Lu Zhang, Founder and Managing Partner of Fusion Fund, brings the viewpoint of an early-stage venture capitalist focused on innovation at the intersection of healthcare and technology. Shalabh Gupta, CEO of Unicycive, contributes the perspective of a public biotech leader advancing therapies through clinical and regulatory pathways. Together, they will explore what distinguishes promising healthcare innovation from solutions that can truly scale, as AI, digital infrastructure, and new therapeutic models continue to reshape medicine.
We will discuss
- What actually scales in AI-driven healthcare—and why many promising tools fail after pilot programs.
- How investors, founders, and healthcare leaders evaluate clinical adoption, workflow integration, regulatory reality, and commercial traction.
- How capital, technology, and leadership can accelerate healthcare innovation while maintaining trust, safety, and real-world impact.
May 26, 2026
5:30 - 7:30 PM
Pillsbury Winthrop Shaw Pittman LLP
4 Embarcadero Ctr
San Francisco, CA 94111
Ticket prices:
HCSF members: $25
HBSANC members: $25
MITNC members: $25
HBSHAA members: $25
Non members: $45
Click here to register
Registration deadline: May 24, 2025
Not a member? Register here for membership!
All new grads are eligible for a one-year-free membership at the Harvard Club of San Francisco. Please register online
Event Registration (Harvard Alumni):
Please sign in with your HarvardKey otherwise a duplicate record will be created and you will not be able to log-in.
No HarvardKey? Please retrieve your HarvardKey here. If you need help, email ithelp@harvard.edu or call 617-495-7777
Panelists:
Shalabh Gupta, MD, MPA
Shalabh Gupta, MD, is a board-certified physician with over two decades of biotech entrepreneurial and leadership experience. He has a proven track record of building companies from scratch, in-licensing assets, raising capital, hiring key executives, and advancing new products.
Dr. Gupta founded Unicycive Therapeutics Inc. (UNCY) in 2016 with no capital, assets, or employees, transforming it into a public biotech company via a straight IPO on Nasdaq. As Founder, Chairman, and CEO, he oversees multiple drug candidates for treating kidney disease and has raised over $170MM from leading healthcare institutional investors.
Previously, he served in commercial strategy at Genentech, Inc., equity research covering US pharmaceuticals at UBS Investment Bank, and equity research covering biotechnology at Rodman & Renshaw.
Dr. Gupta advises Stanford's StartX program, mentoring start-ups across biotech, medtech, and health tech. Since 2020, he has also advised the UCSF Innovation Center.
Jeff Tangney
Jeff is the Co-founder and Chief Executive Officer of Doximity. He also serves as a member of the company’s board of directors. Since launch, Jeff has led through the founding principle of “physicians first” emphasizing the goal of keeping care-givers and their needs central to all of the company’s major decisions. Prior to Doximity, Jeff co-founded Epocrates, Inc., a mobile medical reference app, where he held various management positions including chief operating officer and executive vice president of sales and marketing. Jeff worked as a healthcare investment analyst at Goldman Sachs, and a manager of software development at ZS Associates, a consulting and professional services firm. He holds a B.S. in Economics and Math from the University of Wisconsin-Madison and an M.B.A. from the Stanford Graduate School of Business.
Reema Khan
Reema Khan is the founder and CEO of Green Sands Equity, a Silicon Valley and Zurich-based venture capital firm investing in AI, Deep Tech, and Space through a geopolitical and macroeconomic lens. Fortune ranked the firm among the top 11 U.S. investors in 2022, with a portfolio including SpaceX, Axiom Space, Pasqal, Colossal, Paradromics, Spotify, and Airbnb. She advises CEOs of major deep tech companies and received the 2026 Ellis Island Congressional Medal of Honor.
Since 2018, Khan has served as a UN ambassador for the Royal Academy of Science International Trust and chairs the SETI Institute's Endowment as a trustee. Her philanthropy includes endowing the Green Sands AI Fund at MIT and the SAGE program at SLAC Stanford. She presents the annual "Green Sands Prize" to influential leaders such as Jill Tarter, Rosie Rios, Gwynne Shotwell, and Kizzmekia Corbett, and lectures on diplomacy, investment, and entrepreneurship at Stanford and Berkeley Haas.
Lu Zhang
Lu Zhang, Founder and Managing Partner of Fusion Fund, is a renowned Silicon Valley-based investor, a serial entrepreneur, and a Stanford Engineering alumna. Lu has deep domain expertise in AI in healthcare, Enterprise AI/Networks, Edge Computing, and Data Privacy. Lu started Fusion Fund in 2015. Since then, Lu has built a distinguished eco system and established her reputation in the VC industry. Lu frequently speaks at conferences such as World Economic Forum(Davos), Future Investment Initiative (FII), Web Summit, SuperReturn, etc. and she is also an instructor at Stanford University. Lu serves as a board member of many portfolio companies, the board director of CommonSpirit Health Foundation, the Board of the Youth Council of Future Science Award, and Jury Board of the Cartier Women Initiative. She holds an M.S. in Materials Science and Engineering from Stanford University.
Organizer:
Anupam Agarwal, MPH ‘05,
anupam_agarwal@post.harvard.edu